Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
A pharmaceutical composition comprising: an active ingredient consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, salt thereof, or solvate of the foregoing; and (i) a compound, a 5% (w/w) aqueous solution or suspension of which has a pH of 8 or more, and/or (ii) silicic acid, salt thereof, or solvate of the foregoing is a highly stable pharmaceutical composition, wherein under humidified and heated storage conditions, the decomposition of said compound is sufficiently reduced, or the gelation on the surface of the pharmaceutical composition is sufficiently inhibited.
1. A pharmaceutical composition comprising:
an active ingredient consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a salt thereof;
(i) 1-10 w/w % of one or more compounds selected from the group consisting of magnesium oxide, sodium carbonate, disodium hydrogenphosphate, sodium citrate, dipotassium hydrogenphosphate, sodium acetate, sodium hydrogencarbonate, and sodium hydroxide, and
(ii) one or more compounds selected from the group consisting of light anhydrous silicic acid, silicon dioxide hydrate, and calcium silicate.
2. The pharmaceutical composition according to claim 1 , wherein the compound (i) is magnesium oxide.
3. The pharmaceutical composition according to claim 1 , wherein the active ingredient is crystals of hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate, or ethansulfonate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.
4. The pharmaceutical composition according to claim 1 , where the active ingredient is crystals of methanesulfonate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.
5. The pharmaceutical composition according to claim 1 , wherein the compound (i) is magnesium oxide, and the compound (ii) is light anhydrous silicic acid.
6. The pharmaceutical composition according to claim 1 , wherein the compound (i) is magnesium oxide, disodium hydrogenphosphate, sodium hydrogencarbonate, or sodium hydroxide, and the compound (ii) is light anhydrous silicic acid.
7. The pharmaceutical composition according to claim 1 , wherein the compound (i) is magnesium oxide or disodium hydrogenphosphate, and the compound (ii) is one of light anhydrous silicic acid, silicon dioxide hydrate or calcium silicate.